Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA versus DARVON N W ASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA versus DARVON N W ASA.
ANEXSIA vs DARVON-N W/ ASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, fever, and inflammation.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
1-2 capsules (propoxyphene napsylate 100 mg / aspirin 325 mg per capsule) orally every 4 hours as needed for pain; maximum 6 capsules per day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Propoxyphene: terminal elimination half-life is 6-12 hours in adults with normal renal function; norpropoxyphene has a longer half-life (30-36 hours). Aspirin (as salicylate): half-life is dose-dependent, ranging from 2-3 hours at low doses to 15-30 hours at anti-inflammatory doses (300-600 mg in Darvon-N W/ASA).
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Renal: propoxyphene and its metabolites (norpropoxyphene) are primarily eliminated via kidneys, with ~20-25% excreted unchanged; fecal: minor; biliary: some enterohepatic recirculation occurs, but exact % are not well quantified for the combination product. Aspirin is hydrolyzed to salicylate, which is excreted renally (75% as salicyluric acid, 10% as salicylic acid, 10% as glucuronide conjugates, and minor amounts as gentisic acid).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination